Akorn Names Erislandy (Dandy) Dorado-Boladeres as Executive Vice President of Global Quality
March 21 2019 - 7:00AM
Akorn, Inc. (NASDAQ: AKRX), today announced that Dandy
Dorado-Boladeres has been named as Executive Vice President of
Global Quality, effective March 25, 2019. Mr. Dorado brings
decades of pharmaceutical industry experience and expertise with a
focus on operational quality and technical services. Mr. Dorado
will report directly to Douglas Boothe, Akorn’s President and Chief
Executive Officer, and play a critical role leading Akorn’s efforts
to improve its operational efficiency and quality compliance. His
experience and leadership will be a significant benefit as Akorn
continues to promote a culture of compliance with an emphasis on
safety, quality, performance and integrity.
Most recently, Mr. Dorado served as Vice President of Quality
Affairs at American Regent, where he served on the executive
leadership team. Previously, he served as a Sr. Vice President of
Global Quality Services at Teva and VP of International Quality
Operations at Allergan/Actavis where he successfully led the
integration of the Actavis Generics Quality Services unit with
Teva. He also served in a variety of roles at Actavis
Pharmaceuticals where he led efforts to implement standardized
best-practices across 32 manufacturing sites in 17 countries. Prior
to his tenure at Actavis, Mr. Dorado held a number of technical
operational roles across the pharmaceuticals industry. He graduated
with a B.S. in Chemistry from the University of Puerto Rico.
Douglas Boothe, President & CEO of Akorn, commented, “We are
very pleased to announce Dandy as the newest member of the Akorn
leadership team. Dandy’s deep expertise leading pharmaceutical
organizations through challenging times will further strengthen
Akorn. All quality functions will now be reporting to Dandy as part
of our emphasis on accountability and cross-functional
collaboration.”
About Akorn Akorn, Inc. is a
specialty generic pharmaceutical company engaged in the
development, manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website
at www.akorn.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release includes statements that may
constitute "forward-looking statements", including expectations
regarding operational efficiency, quality compliance, safety,
performance, growth and other statements regarding Akorn’s plans
and strategy. When used in this document, the words “will,”
“expect,” “continue," “believe,” “anticipate,” “estimate,”
“intend,” “could,” “strives” and similar expressions are generally
intended to identify forward-looking statements. These statements
are made pursuant to the safe harbor provisions of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. A number of important
factors could cause actual results of Akorn and its subsidiaries to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to: (i) the
effect of the Delaware court’s recent decision against Akorn on
Akorn’s ability to retain and hire key personnel, its ability to
maintain relationships with its customers, suppliers and others
with whom it does business, or its operating results and business
generally, (ii) the risk that ongoing or future litigation related
to the court’s decision may result in significant costs of defense,
indemnification and/or liability, (iii) the outcome of the
investigation conducted by Akorn with the assistance of outside
consultants, into alleged breaches of FDA data integrity
requirements relating to product development at Akorn and any
actions taken by Akorn, third parties or the FDA as a result of
such investigations, (iv) the difficulty of predicting the timing
or outcome of product development efforts, including FDA and other
regulatory agency approvals and actions, if any, (v) the timing and
success of product launches, (vi) difficulties or delays in
manufacturing, and (vii) such other risks and uncertainties
outlined in the risk factors detailed in Part I, Item 1A, “Risk
Factors,” of Akorn’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2018 (as filed with the Securities and Exchange
Commission (“SEC”) on March 1, 2019) and other risk factors
identified from time to time in our filings with the SEC. Readers
should carefully review these risk factors, and should not place
undue reliance on our forward-looking statements. These
forward-looking statements are based on information, plans and
estimates at the date of this report. Akorn undertakes no
obligation to update any forward-looking statements to reflect
changes in underlying assumptions or factors, new information,
future events or other changes.
Investors: (847) 279-6162
Investor.relations@akorn.com
Media: Robert Stanislaro / Camilla White
212-850-5600
Robert.Stanislaro@fticonsulting.com / Camilla.White@fticonsulting.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Sep 2023 to Sep 2024